Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENIA11 in Ankylosing Spondylitis
NCT02685904Phase 3Terminated
- Sponsor
- Mycenax Biotech Inc.
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etanercept in ankylosing spondylitis (AS) (2 arms), sponsored by Mycenax Biotech Inc. Primary endpoint: Assessment in Ankylosing Spondylitis 20% Response at 12 weeks. Started Sep 2016; status: terminated.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02685904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685904.